This study provides clinical reference value, showing that a ΔΔLFC of −5.2% corresponds with reductions of −21.6 U/L in ALT and −12.3 U/L in AST, offering valuable insights for NAFLD treatment development. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.